Skip to main content

$0.100 -0.005 (-4.76%)

High

$0.11

Low

$0.10

Trades

225

Turnover

$176,834

Volume

1,754,344
30 June 2023 at 4:10pm
Register to track IHL and receive email alerts.
Subject
IHL Ann: Notice of Annual General Meeting/Proxy Form

IHL Ann: Application for quotation of securities - IHL

IHL Ann: Positive preliminary data from IHL-675A Ph 1 trial

IHL Ann: Positive Pre-IND Meeting with US FDA on IHL-216A

IHL Ann: Annual General Meeting Date

IHL Ann: Appendix 4G

IHL Ann: Annual Report

IHL Ann: Incannex Presenting at H.C. Wainwright Global Conference

IHL Ann: Incannex Included in the S&P/ASX 300 Index

IHL Ann: S&P DJI Announces September 2022 Quarterly Rebalance

IHL Ann: Appendix 4E & Unaudited Accounts for Year Ended 30 June 2022

IHL Ann: Appendix 3Y

IHL Ann: Appendix 3X, Form 605 and Appendix 3Y

IHL Ann: Incannex Appoints Distinguished FDA Expert to Board

IHL Ann: Notification regarding unquoted securities - IHL

IHL Ann: Application for quotation of securities - IHL

IHL Ann: Notification regarding unquoted securities - IHL

IHL Ann: Application for quotation of securities - IHL

IHL Ann: Incannex Healthcare Company Overview

IHL Ann: Notification regarding unquoted securities - IHL

IHL Ann: Application for quotation of securities - IHL

IHL Ann: Incannex Completes Acquisition of APIRx

IHL Ann: Proposed issue of securities - IHL

IHL Ann: IHL Engages Curia to Scale-up Manufacture of cGMP IHL-216A

IHL Ann: Quarterly Activities/Appendix 4C Cash Flow Report

IHL Ann: Ethics Approval Received to start Ph 1 Clinical of IHL 675A

IHL Ann: Change of Auditor

IHL Ann: Cleansing Notice

IHL Ann: Director's Initial and Final Interest Notice

IHL Ann: Application for quotation of securities - IHL

IHL Ann: Notification regarding unquoted securities - IHL

IHL Ann: Proposed issue of securities - IHL

IHL Ann: Director and management update

IHL Ann: Incannex to Present at the H.C. Wainwright Conferecne

IHL Ann: Notification regarding unquoted securities - IHL

IHL Ann: Application for quotation of securities - IHL

IHL Ann: Appendix 2A and 3G, Cleansing Notice

IHL Ann: Results of Meeting

IHL Ann: IHL-42X phase 2 clinical trial presentation

IHL Ann: Positive final results from IHL-42X phase 2 trial

IHL Ann: Correction to Notice of General Meeting

IHL Ann: Positive FDA Pre-IND meeting guides IHL-42X development

IHL Ann: APIRx Acquisition Presentation

IHL Ann: Incannex completes APIRx Share Sale and Purchase Agreement

IHL Ann: Notice of General Meeting/Proxy Form

IHL Ann: IHL-216A Preclinical Study Results

IHL Ann: Trading Halt

IHL Ann: Application for quotation of securities - IHL

IHL Ann: Proposed issue of securities - IHL

IHL Ann: Appendix 2A

Register to track IHL and receive email alerts.

Similar Companies

CAN
CPH
EOF
MVP
MYX
NEU
PBP
RCE
SPL